4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0000950170-25-078552
Chief Operating Officer sold 40,673 shares at an average $104.07 ($4,232,636)
- Chief Operating Officer acquired 40,673 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. Chief Operating Officer | 2025-05-27 | Option exercise 10b5-1 | +20,673 | $6.47 | $133,754 | 26,456 | D |
| Jacobson Mark L. Chief Operating Officer | 2025-05-27 | Sale 10b5-1 | −20,673 | $104.66 | $2,163,636 | 5,783 | D |
| Jacobson Mark L. Chief Operating Officer | 2025-05-28 | Option exercise 10b5-1 | +20,000 | $6.47 | $129,400 | 25,783 | D |
| Jacobson Mark L. Chief Operating Officer | 2025-05-28 | Sale 10b5-1 | −20,000 | $103.45 | $2,069,000 | 5,783 | D |
| Derivatives | |||||||
| Jacobson Mark L. Chief Operating Officer | 2025-05-27 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,673 | 0 | D | ||
| Jacobson Mark L. Chief Operating Officer | 2025-05-28 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 0 | D | ||
| Open-market sales · 40,673 sh · avg $104.07 · $4,232,636 | |||||||
Loading xslF345X05/ownership.xml…